Ind. J. Pharm. Edu. Res., 2026; 60(2s):s430-s435.
https://www.ijper.org

Review Article

Quality by Design (QbD) Approach in the Formulation of Liposomal Gel: A Review

Attuluri V S Himabindu[1,*], Alla Seetha Devi[2]

[1]Department of Pharmaceutics, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, INDIA.
[2]Department of Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Bachupally, Hyderabad, Telangana, INDIA.

ABSTRACT

Liposomal gels represent an advanced drug delivery system that combines the benefits of liposomal encapsulation with the controlled release properties of gels, offering enhanced therapeutic efficacy, stability and patient compliance. Quality by Design (QbD) is a systematic approach to pharmaceutical development, focusing on predefined objectives and emphasizing product and process understanding. This review explores the application of QbD principles in the formulation of liposomal gels, discussing key aspects such as defining the Quality Target Product Profile (QTPP), identifying Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) and the implementation of Design of Experiments (DoE) for optimization. The article also covers risk assessment, control strategies and the regulatory benefits of the QbD approach in ensuring consistent product quality. Challenges and future directions for the application of QbD in the development of liposomal gel formulations are also addressed.

Keywords: Critical Quality Attributes, Liposomes, Quality by Design, Risk Assessment.

Correspondence:
Mrs. Attuluri V S Himabindu
Research Scholar, Associate Professor, Department of Pharmaceutics, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur-522510, Andhra Pradesh, INDIA.
Email: himabindu.pharma1@gmail.com

Received: 17-04-2025;
Revised: 09-06-2025;
Accepted: 28-08-2025.

INTRODUCTION

Overview of Liposomal Drug Delivery Systems

Liposomal drug delivery systems have been widely explored in pharmaceutical formulations due to their ability to encapsulate both hydrophilic and lipophilic drugs. Liposomes are vesicular structures consisting of phospholipid bilayers, which can encapsulate Active Pharmaceutical Ingredients (APIs), offering protection from degradation and enhancing bioavailability. The unique characteristics of liposomes, such as their ability to target specific tissues and provide controlled release, make them ideal for drug delivery, particularly in topical and transdermal applications.

Liposomal gels combine the advantages of liposomes with those of semi-solid gels, which are easy to apply, spread and absorb. The gel matrix helps control the release rate of the drug, making the formulation suitable for prolonged therapeutic effects, especially for localized treatment of skin disorders, infections, or inflammation. However, the development of such complex systems requires a robust and systematic approach to ensure quality, stability and efficacy.

Challenges in Developing Liposomal Formulations

Developing stable liposomal formulations presents several challenges, including maintaining the size and integrity of liposomes within the gel matrix, achieving high encapsulation efficiency and ensuring controlled release of the drug. In addition, the interaction between the liposomes and the gel matrix can affect the product's stability and performance. As a result, achieving consistent product quality necessitates a comprehensive understanding of both the formulation components and the manufacturing process.[1-3]

Overview of Quality by Design (QbD)

Quality by Design (QbD) is a scientific, risk-based approach to pharmaceutical product development that focuses on ensuring quality is built into the product from the outset. Rather than relying on end-product testing alone, QbD emphasizes a thorough understanding of the product and process, identifying critical variables and controlling them to minimize variability. This approach aligns with regulatory expectations set by agencies such as the FDA and EMA, which encourage manufacturers to adopt QbD principles for more consistent, predictable outcomes.

Relevance of QbD in Liposomal Gel Development

The application of QbD in liposomal gel development ensures that the product meets predefined quality attributes while minimizing

DOI: 10.5530/ijper.20260963

the likelihood of formulation failures. By understanding the interaction between the liposome vesicles, the drug and the gel matrix, a QbD approach allows formulators to design a robust product that delivers consistent therapeutic benefits (Figure 1). Moreover, QbD aids in optimizing the manufacturing process, ensuring scale-up feasibility and improving regulatory compliance.[4-6]

Quality Target Product Profile (QTPP) and Critical Quality Attributes (CQAs)

Defining the Quality Target Product Profile (QTPP)

The QTPP is a crucial element in the QbD approach, serving as the blueprint for product development. It defines the desired product characteristics, such as the intended therapeutic use, dosage form, route of administration and desired release profile. For liposomal gels, the QTPP may include factors such as:

- **Therapeutic application:** Localized treatment for skin diseases or transdermal delivery.
- **Dosage form:** Semi-solid gel containing liposome-encapsulated drugs.
- **Release profile:** Controlled or sustained release over a specific period.
- **Stability:** Ensuring long-term stability of the liposomes in the gel matrix.
- **Patient acceptability:** Non-irritating, easily spreadable and cosmetically acceptable.

The QTPP acts as a guide throughout the development process, ensuring that the formulation meets the necessary quality standards.

Identifying Critical Quality Attributes (CQAs)

CQAs are the physical, chemical, biological, or microbiological properties of the product that must be controlled to ensure the desired quality and performance (Figure 2). In the context of liposomal gels, CQAs typically include:

- **Liposome size and Polydispersity Index (PDI):** These parameters affect drug encapsulation efficiency, release rate and penetration through the skin.
- **Encapsulation efficiency:** The percentage of the active drug successfully encapsulated within the liposomes. Higher encapsulation efficiency improves therapeutic efficacy.
- **Gel viscosity:** Viscosity impacts the application properties and release kinetics of the drug.
- **pH of the formulation:** The pH affects both the stability of the drug and the patient's skin compatibility.
- **Drug release profile:** This determines how quickly and efficiently the drug is released from the liposomal gel.
- **Stability:** The physical and chemical stability of the liposomal gel over time, including maintaining the integrity of the liposomes.

Each CQA must be carefully monitored and controlled during formulation development to ensure the final product's quality, efficacy and safety.[7-9]

Risk Assessment: Identifying Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs)

Risk Management and ICH Q9 Guidelines

Risk assessment plays a pivotal role in the QbD framework and is guided by ICH Q9 recommendations on quality risk management. The risk assessment process identifies potential factors that could impact the CQAs and helps prioritize them for control during formulation and manufacturing. Tools such as Failure Mode and Effects Analysis (FMEA) and Ishikawa diagrams are commonly used to evaluate risks.

Critical Material Attributes (CMAs)

CMAs refer to the properties of raw materials used in the formulation, which have a direct impact on the CQAs. For liposomal gels, the key CMAs include:

- **Lipid type and purity:** The choice of phospholipids and their purity affect the stability and formation of liposomes.
- **Drug solubility:** The solubility of the drug in both the liposomal phase and the gel matrix is critical to achieving the desired encapsulation efficiency and release profile.
- **Gelling agents:** The concentration and type of gelling agents (e.g., carbomers, HPMC) determine the viscosity and consistency of the final gel.
- **Surfactants:** Surfactants may be used to stabilize the liposomes within the gel matrix, but their concentration must be optimized to avoid destabilization of the liposomes.

Critical Process Parameters (CPPs)

CPPs are key manufacturing parameters that must be controlled to ensure that the CQAs are met. For liposomal gel formulations, these may include:

- **Liposomal preparation method:** Techniques such as thin-film hydration, sonication, or extrusion impact the size, uniformity and encapsulation efficiency of the liposomes.

- **Homogenization pressure:** High-pressure homogenization can reduce the liposome size and improve encapsulation, but excessive pressure may damage the liposomes.
- **Mixing speed and time:** During gel preparation, the rate and duration of mixing affect the distribution of liposomes within the gel matrix.
- **Temperature control:** Both liposome preparation and gel formulation processes must be carried out at controlled temperatures to prevent degradation of the lipids and the drug.[10,11]

Risk Assessment Tools in Liposomal Gel Development

Risk assessment tools like FMEA and Ishikawa diagrams are used to systematically evaluate the impact of various CMAs and CPPs on the CQAs. By identifying the most critical factors, formulators can focus on controlling these variables to minimize product variability and ensure quality.

Design of Experiments (DoE) in Formulation Optimization

Role of Design of Experiments in QbD

Design of Experiments (DoE) is a powerful tool used in QbD to optimize the formulation and manufacturing process (Figure 3). DoE involves systematically varying multiple factors to understand their impact on CQAs and identifying optimal conditions for formulation development. By using DoE, formulators can identify interactions between variables, such as the effect of lipid concentration on encapsulation efficiency and liposome size.

Factorial Design for Screening Variables

Factorial designs are commonly used in the initial stages of formulation development to screen multiple variables and determine their impact on CQAs. For example, a factorial design can be used to study the effect of lipid-to-drug ratio, surfactant concentration and homogenization pressure on the size and encapsulation efficiency of liposomes in a gel formulation.

Response Surface Methodology (RSM) for Optimization

Once the critical factors are identified, Response Surface Methodology (RSM) is applied to fine-tune the formulation. RSM allows for the optimization of multiple variables to achieve the desired CQAs. For example, RSM can help determine the optimal ratio of gelling agents and lipids to achieve a gel with the appropriate viscosity, drug release rate and stability.[12-14]

Case Studies on DoE in Liposomal Gel Formulation

Several studies have demonstrated the successful application of DoE in optimizing liposomal gel formulations. For instance, researchers have used DoE to optimize the encapsulation efficiency and release profile of a liposomal gel containing anti-inflammatory drugs. Through systematic experimentation, they were able to achieve an optimal balance between drug loading, stability and release.[15,16]

Control Strategy for Consistency in Manufacturing

Implementing a Control Strategy

A robust control strategy is essential to ensure the consistency and quality of liposomal gels during manufacturing. The control strategy involves monitoring and controlling both CPPs and CMAs throughout the production process to ensure that CQAs are consistently met.



Figure 1: Flowchart of the QbD Approach in Formulation Development.



Figure 2: Factors that might have impact on liposomal PLP concentration and the encapsulation efficiency.



Figure 3: Process optimization by use of Design of Experiments.

In-Process Controls (IPCs)

In-Process Controls (IPCs) are used to monitor critical parameters during manufacturing, such as liposome size, pH and viscosity. Real-time monitoring of these parameters allows for immediate corrective actions if deviations occur, ensuring that the final product meets the required quality standards.

End-Product Testing

End-product testing is performed to confirm that the final liposomal gel meets the predefined CQAs. Key tests include:

- **Drug content uniformity:** Ensuring the drug is evenly distributed throughout the gel.
- **Viscosity testing:** Ensuring the gel has the appropriate consistency for easy application.

- **Stability testing:** Evaluating the long-term stability of the liposomal gel under various conditions (temperature, humidity).
- ***In vitro* drug release studies:** Confirming that the drug is released from the gel at the desired rate.

Stability and Shelf-Life Considerations

Stability studies are critical for liposomal gels, as the integrity of the liposomes must be maintained over time to ensure the product's efficacy. These studies involve storing the product under different conditions and monitoring the CQAs over time to establish the shelf-life of the product.[17,18]

Regulatory Aspects and Benefits of QbD Implementation

Regulatory Requirements for Liposomal Drug Products

Liposomal drug products are subject to stringent regulatory scrutiny due to their complex nature. Regulatory agencies such as the FDA and EMA require detailed information on the formulation and manufacturing process, including data on CQAs, CMAs and CPPs. The QbD approach provides a systematic framework for generating this data, which facilitates regulatory approval.

Advantages of QbD in Regulatory Submissions

The adoption of QbD principles in the development of liposomal gels offers several advantages in regulatory submissions. By providing comprehensive data on the formulation and process, manufacturers can demonstrate a thorough understanding of the product's quality and consistency. This reduces the likelihood of regulatory delays and increases the chances of a successful product approval.

Future Directions and Challenges in QbD for Liposomal Gels

Advancements in Liposomal Gel Technologies

Emerging technologies and novel materials hold great promise for improving liposomal gel formulations. Innovations in liposome preparation techniques, the use of advanced gelling agents and the development of new drug molecules for liposomal delivery are areas of active research.

Challenges in the Implementation of QbD for Liposomal Gels

Despite the benefits of QbD, challenges remain in its application to liposomal gels. These include the complexity of scaling up the manufacturing process, ensuring batch-to-batch consistency and developing advanced analytical techniques to monitor CQAs in real-time.

Potential for Personalized Medicine

The QbD framework could be extended to the development of personalized liposomal gels, tailored to individual patients' needs. This approach has the potential to revolutionize the treatment of diseases by providing targeted, patient-specific therapies.[19,20]

CONCLUSION

The application of QbD principles in the formulation of liposomal gels offers a systematic approach to ensuring product quality, consistency and regulatory compliance. By focusing on a deep understanding of both the formulation components and the manufacturing process, QbD allows for the optimization of critical parameters, resulting in a robust and effective drug delivery system. As the field continues to evolve, the integration of QbD with emerging technologies and personalized medicine offers exciting opportunities for the future of liposomal gel development.

ACKNOWLEDGEMENT

The authors acknowledge University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur for providing support to carry out the work.

ABBREVIATIONS

QbD: Quality by Design; **QTTP:** Quality Target Product Profile; **CQAs:** Critical Quality Attributes; **CMA:** Critical Material Attributes; **CPPs:** Critical Process Parameters; **DoE:** Design of Experiments; **PAT:** Process Analytical Technologies.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

SUMMARY

The Quality by Design (QbD) approach in the formulation of liposomal gels focuses on integrating quality into the product development process from the beginning, rather than relying solely on end-product testing. This systematic approach emphasizes understanding the relationship between formulation components, process parameters and the final product's quality attributes. In the case of liposomal gels, QbD helps optimize the formulation to achieve consistent product quality, safety and efficacy. It involves identifying Critical Quality Attributes (CQAs) such as particle size, drug encapsulation efficiency, gel viscosity and stability. A comprehensive risk assessment is performed to evaluate potential variations in formulation ingredients and manufacturing processes, helping to identify Critical Process Parameters (CPPs) that can influence CQAs. By utilizing tools like Design of Experiments (DoE), Process Analytical Technologies (PAT) and robust statistical methods, the QbD approach enables the development of liposomal gels that are reproducible and of

high quality. This approach also aims to ensure better regulatory compliance and faster product development by minimizing trial-and-error approaches, improving product performance and ensuring patient safety.

REFERENCES

1. ICH Q8 (R2) Pharmaceutical Development. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2009.
2. Food and Drug Administration. Guidance for Industry: Liposome Drug Products. US Department of Health and Human Services; 2018.
3. Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160(2): 117-34.
4. Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett. 2005; 10(4): 711-9.
5. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4(2): 145-60.
6. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001; 47(2-3): 165-96.
7. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013; 65(1): 36-48.
8. Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev. 2012; 112(11): 5818-78.
9. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2012; 64(1): 24-36.
10. Betageri GV, Jenkins SA, Parsons DL. Liposomal formulations of poorly soluble drugs. Pharm Technol. 1993; 17(3): 44-50.
11. Atraki R, Tayebi L, Lotfipour F. Quality by design (QbD) approach to pharmaceutical development. Int J Pharm Res. 2014; 6(1): 9-19.
12. Zhai G, Zhang X, Wu J, Wang Y. Quality by Design (QbD) approach in pharmaceutical development. Acta Pharm Sin B. 2020; 10(4): 583-602.
13. Jain S, Kumar D, Swarnakar NK, Thanki K. Polymers in the advancement of nanoparticle drug delivery systems. In: Domb AJ, Kumar N, editors. Biodegradable Polymers in Clinical Use and Clinical Development. Hoboken: John Wiley and Sons; 2011. p. 445-98.
14. Singh B, Sharma T, Kumar A, Ahuja N. Application of quality by design approach to optimized development of novel chemical entities with advanced therapeutic potential. Eur J Pharm Sci. 2017; 107: 239-52.
15. Charcosset C, Juban A, Valour JP, Urbaniak S, Fessi H. Preparation of liposomes at large scale using the ethanol injection method: effect of scale-up and injection devices. Chem Eng Res Des. 2015; 104: 1-8.
16. Langguth P, Lipp R. Targeted delivery using liposomal formulations: success stories and future challenges. Adv Drug Deliv Rev. 2021; 172: 149-76.
17. Laouini A, Jaafar-Maalej C, Sfar S, Charcosset C, Fessi H. Liposome preparation using a hollow fiber membrane contactor: influence of experimental conditions on vesicle size. Int J Pharm. 2011; 415(1-2): 53-61.
18. Chen Y, Shen Q. Quality by design for nanosuspensions: toward a better understanding of the pharmaceutical development process. J Pharm Sci. 2018; 107(4): 1107-21.
19. Xu X, Khan MA, Burgess DJ. Predicting hydrophilic drug encapsulation inside unilamellar liposomes. Int J Pharm. 2012; 423(2): 410-8.
20. Chawla A, Saraf SA. Quality by design: A systematic approach to pharmaceutical development. Int J Pharm Pharm Sci. 2014; 6(2): 1-5.

Cite this article: Himabindu AVS, Devi AS. Quality by Design (QbD) Approach in the Formulation of Liposomal Gel: A Review. Indian J of Pharmaceutical Education and Research. 2026;60(2s):s430-s435.